ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 68 filers reported holding ADC THERAPEUTICS SA in Q3 2022. The put-call ratio across all filers is 2.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,606,431 | -61.9% | 2,905,721 | -8.7% | 0.00% | 0.0% |
| Q2 2023 | $6,839,685 | +3.8% | 3,181,249 | -5.9% | 0.00% | 0.0% |
| Q1 2023 | $6,589,448 | -14.3% | 3,379,204 | +68.8% | 0.00% | -50.0% |
| Q4 2022 | $7,685,253 | +3062.7% | 2,001,368 | +3879.6% | 0.00% | – |
| Q3 2022 | $243,000 | -11.6% | 50,291 | +45.3% | 0.00% | – |
| Q2 2022 | $275,000 | -39.6% | 34,600 | +11.6% | 0.00% | – |
| Q1 2022 | $455,000 | +3.4% | 31,000 | +42.2% | 0.00% | – |
| Q4 2021 | $440,000 | -16.2% | 21,800 | +12.7% | 0.00% | – |
| Q3 2021 | $525,000 | -67.5% | 19,346 | -70.8% | 0.00% | – |
| Q2 2021 | $1,614,000 | +30.0% | 66,299 | +30.4% | 0.00% | – |
| Q1 2021 | $1,242,000 | -57.8% | 50,862 | -44.7% | 0.00% | -100.0% |
| Q4 2020 | $2,944,000 | +111.5% | 91,998 | +209.4% | 0.00% | – |
| Q2 2020 | $1,392,000 | – | 29,738 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 5,402,041 | $4,845,631 | 1.54% |
| Sio Capital Management, LLC | 3,294,534 | $2,955,197 | 0.92% |
| Redmile Group, LLC | 14,178,045 | $12,717,706 | 0.60% |
| AlphaCentric Advisors LLC | 1,068,468 | $958,416 | 0.54% |
| Vantage Consulting Group Inc | 850,737 | $763,111 | 0.51% |
| Blue Owl Capital Holdings LP | 733,568 | $654,489 | 0.51% |
| Affinity Asset Advisors, LLC | 1,100,000 | $986,700 | 0.28% |
| Frazier Life Sciences Management, L.P. | 1,647,030 | $1,477,386 | 0.10% |
| Indie Asset Partners, LLC | 92,700 | $83,152 | 0.08% |
| GCM Grosvenor Holdings, LLC | 410,888 | $368,567 | 0.07% |